MGMT and glioblastoma: PARP inhibitors may introduce novel poly(ADP-ribosyl)ation modifications to MGMT, thereby neutralizing its function and enhancing the susceptibility of MGMT wild-type glioblastoma to temozolomide-induced cytotoxicity (46).